QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ZVRA

QT78Zevra Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
12.90
+0.29+2.30%
OverviewShort InterestFilings
ZVRAQT78Zevra Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
12.90+2.30%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E5.93EPS (ttm)
2.15
Insider Own3.73%
Shs Outstand59.12M
Perf Week-0.54%
Market Cap745.44MForward P/E13.89EPS next Y0.93Insider Trans1.58%Shs Float-Perf Month26.47%
Enterprise Value650.99MPEG0.00EPS next Q0.08Inst Own-Short Float-Perf Quarter37.23%
Income125.76MP/S6.10EPS this Y-50.44%Inst Trans-Short Ratio-Perf Half Y58.87%
Sales122.29MP/B3.58EPS next Y-12.83%ROA44.59%Short Interest-Perf YTD43.97%
Book/sh3.48P/C57.69EPS next 5Y30.40%ROE81.34%52W High14.27 -9.60%Perf Year46.42%
Cash/sh1.62P/FCF62.15EPS past 3/5Y-ROIC-19.57%52W Low7.16 80.17%Perf 3Y-
Dividend Est.-EV/EBITDA4.63Sales past 3/5Y119.67% 52.15%Gross Margin85.51%Volatility3.83% 4.09%Perf 5Y-
Dividend TTM-EV/Sales5.32EPS Y/Y TTM211.40%Oper. Margin-39.86%ATR (14)0.71Perf 10Y-
Dividend Ex-Date-Quick Ratio4.84Sales Y/Y TTM408.33%Profit Margin101.58%RSI (14)61.85Recom2.00
Dividend Gr. 3/5Y-Current Ratio4.89EPS Q/Q400.00%SMA209.57%Beta0.70Target Price29.75
Payout0.00%Debt/Eq0.01Sales Q/Q80.00%SMA5017.79%Rel Volume1.18Prev Close12.61
Employees59LT Debt/Eq0.41EarningsAug 11SMA20034.49%Avg Volume1.64MPrice12.90
IPO DateApr 16, 2015Option/ShortYes / YesEPS/Sales Surpr.200.00% 12.50%Net Debt/EBITDA-0.67Volume1,947,866Change2.30%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-26ReiteratedGuggenheimBuy$25 → $29
Jun-10-26ReiteratedMaxim GroupBuy$25 → $35
Jun-09-26ReiteratedCanaccord GenuityBuy$24 → $29
May-08-26ReiteratedGuggenheimBuy$23 → $25
Mar-10-26ReiteratedGuggenheimBuy$22 → $23
Dec-30-25ReiteratedH.C. Wainwright$20 → $26
Nov-06-25ReiteratedCantor FitzgeraldOverweight$24
Nov-06-25ReiteratedCanaccord GenuityBuy$22 → $24
Mar-13-25ReiteratedGuggenheimBuy$21 → $22
Mar-12-25ReiteratedJMP Securities$17 → $18
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue12210624
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A18167
Gross Profit1069016
Selling, General and Administrative Excl. Other797855
Research and Development131342
Other Operating Expense6136
Operating Income-49-4-87
Interest Expense887
Unusual Expense
———
Non-Operating Income (Expense)-186-99-4
Net Income Before Taxes13487-90
Income Taxes10315
Consolidated Net Income12483-106
Net Income From Continuing Operations12483-106
Net Income12483-106
EPS (Recurring)2.181.40-2.28
EPS (Basic, Before Extraordinaries)2.181.40-2.28
EPS (Diluted)2.151.35-2.28
EBITDA14099-76
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio6.006.64—
Price To Sales Ratio6.134.65—
Gross Margin86.8984.9166.67
Operating Margin-40.16-3.77-362.50
Net Margin101.6478.30-441.67
Shares Outstanding585546
Market Capitalization748493—
Operating Lease Expense
———
Insider Trading Volume
$13.41$12.50$11.59$10.69$9.78● Close Price0.00M0.28M0.55M0.83M1.10MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Thompson RahsaanChief Legal & ComplianceMay 11 '26Sale11.301,79420,27248,125May 13 12:00 AM
Bode John BDirectorMar 24 '26Option Exercise4.93156,800773,024123,400Mar 26 12:00 AM
McFarlane Neil F.President and CEOFeb 09 '26Sale8.5614,625125,186387,225Feb 10 12:00 AM
McFarlane Neil F.President and CEOFeb 07 '26Option Exercise0.0075,0000401,850Feb 10 12:00 AM
Sangiovanni Timothy J.SVP, Finance & Corp ControllerFeb 03 '26Sale9.183,00027,54829,590Feb 04 12:00 AM
Schafer JoshuaCCOFeb 03 '26Sale9.1910,50096,50062,278Feb 04 12:00 AM
McFarlane Neil F.President and CEOFeb 02 '26Sale9.3891,000853,425364,350Feb 02 12:00 AM
McFarlane Neil F.President and CEOJan 31 '26Option Exercise0.00466,6680455,350Feb 02 12:00 AM
Sangiovanni Timothy J.SVP, Finance & Corp ControllerJan 31 '26Option Exercise0.0023,332032,590Feb 02 12:00 AM
Schafer JoshuaCCOJan 31 '26Option Exercise0.0070,668072,778Feb 02 12:00 AM
Schafer JoshuaCCOJan 30 '26Sale8.833,37529,80037,444Feb 02 12:00 AM
Sangiovanni Timothy J.SVP, Finance & Corp ControllerJan 30 '26Option Exercise0.0012,666022,674Feb 02 12:00 AM
Sangiovanni Timothy J.SVP, Finance & Corp ControllerJan 30 '26Sale8.821,75015,44220,924Feb 02 12:00 AM
Thompson Rahsaanofficer, other: Chief Legal & ComplianceJan 30 '26Option Exercise0.0022,666053,999Feb 02 12:00 AM
Thompson Rahsaanofficer, other: Chief Legal & ComplianceJan 30 '26Sale8.834,08036,01049,919Feb 02 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR